Participants in trial of amycretin injectable obesity drug lost an average of 24% of their body weight on highest dose ...

Novo Nordisk A/S’s latest experimental obesity drug helped patients lose as much as 24.3% of their weight in a small study, ...

The shipments have vaulted Ireland, a country of only five million people, into the second-largest goods-trade imbalance with the U.S., trailing only China.

Protagonist Therapeutics' partners ought to secure two approvals for blockbuster drugs within the next year. Click here to ...

The global peptide therapeutics market size was valued at $33.3 billion in 2021, and is projected to reach $64.3 billion by 2031, growing at a CAGR o ...

Investing.com -- The American College of Cardiology released new recommendations on Friday stating that millions more ...

Novo Nordisk (NVO), and Amgen (NASDAQ:AMGN) are scheduled to present major clinical trial readouts at the American Diabetes ...

Treatments designed to help patients preserve muscle while losing weight with popular obesity drugs by Eli Lilly and Novo ...

Here are some of the stories Wall Street is watching on Friday, June 20. Chipmakers are on the move following a Wall Street ...

GLP-1 drugs such as Wegovy and Zepbound are growing increasingly prominent. But some food ingredients can also cause the body ...

With a backdrop of mounting industry disruption and transition, Pharm Exec’s latest listing of the top global biopharma sales ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.